Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Dialyzable Leukocyte Extracts (DLEs) are low-molecular-weight substances derived from human leukocytes, sometimes referred to as transfer factors. Their use in autoimmune disorders is supported primarily by preliminary scientific studies, though the evidence is limited and not yet conclusive. Research, mostly from Latin America and Eastern Europe, suggests that DLEs may modulate immune responses, possibly by shifting the balance between Th1 and Th2 lymphocyte activity or by enhancing regulatory T cell function. Several small clinical trials and case series have reported benefits in autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. For example, a few early studies and observational reports have noted improvements in clinical symptoms and markers of immune activation after DLE administration. However, these studies are generally small, lack rigorous controls, and are often not blinded. Systematic reviews and meta-analyses are lacking, and the mechanism of action is not yet fully understood. Regulatory agencies such as the FDA have not approved DLE for autoimmune disorders, citing insufficient high-quality evidence. In summary, while there is some scientific investigation and theoretical rationale for the use of DLE in autoimmune disorders, the overall quality of evidence is low (rated 2/5), and more robust, large-scale clinical trials are needed before DLE can be recommended as standard therapy.

More about Dialyzable Leukocyte Extract
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Dialyzable Leukocyte Extract

Products containing Dialyzable Leukocyte Extract